This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (January 6, 2014)


To Our Investors - January 6, 2014 -

Happy New Year! This coming year is going to be an important one for Japan Tissue Engineering (J-TEC).

Off to a good start

Today, January 6, the 2013 Nikkei Superior Products and Services Awards were announced, and J-TEC’s autologous cultured cartilage, JACC, won the top prize, the “Nikkei Awards for Excellence.” The other winning products and services that were selected along with JACC were all ones that everyone knows. I heard that the journalists of the Nikkei Group chose JACC from among approximately 20,000 products and services that were launched in 2013. JACC is also apparently the first winner ever from the field of medical and bio-related products. With this welcome news, 2014 is off to good start.

2014, a year of achievement

President & CEO Yosuke OzawaAmong J-TEC’s business goals, one of the most important is to move into the black in the medium term. Towards that end, it is vital that, with attention in Japan focused on regenerative medicine, we increase the sales of our two approved products: the autologous cultured epidermis, JACE, and the autologous cultured cartilage, JACC. In particular, JACC, which we began selling in April 2013, requires large amounts of time and manpower to train the medical institutions and physicians that use it, but we expect it to become the engine that pulls the company into the black. Moreover, to produce this high-quality product in volume, we will also expand our manufacturing facilities.
In 2014, we hope to achieve growth overseas – where we have been seeking business opportunities over the past several years – as well as positive results from our cooperation with Fujifilm, our largest shareholder.
In 2014, J-TEC will accomplish the industrialization of regenerative medicine by achieving results and growth in our main businesses and by attaining the goal of moving into the black in the medium term.

A system for early approval of regenerative medicine products

From 2012 to 2013, the work of revising the Pharmaceutical Affairs Law progressed with amazing speed. To accelerate the advancement of regenerative medicine, which the Abe administration established as one of its growth strategies, three ministries – the Ministry of Health, Labor and Welfare, the Ministry of Economy, Trade and Industry, and the Ministry of Education, Culture, Sports, Science and Technology – cooperated with each other and, in the end, boldly revised the Pharmaceutical Affairs Law, which governs our industry. It was truly an epoch-making achievement.
Among the revisions related to regenerative medicine products, an early approval system was introduced. It had originally been called a “conditional approval system.” However, it seems that the Ministry of Health, Labor and Welfare emphasized the possibility of “early approval.” As a result, two routes – the normal approval system and an early approval system – have been established for reviews of regenerative medicine products, etc. Before the clinical trial begins, the applicant chooses which route to take.
Due to the introduction of the early approval system, new entries into the marketplace are expected not only from domestic companies but also from foreign companies. Amidst this healthy competition, J-TEC will further build up its corporate strength and contribute to the national and global growth of regenerative medicine. It looks like 2014 is going to be an enjoyable and challenging year.

January 6, 2014
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.